SPINRAZA may offer improvements for important motor milestones

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.

Over 8 years

The safety profile of SPINRAZA has more than 8 years of follow-up data that is consistent with those previously reported.


SPINRAZA is delivered directly to the central nervous system (CNS) where motor neuron loss begins. After 4 initial loading doses, SPINRAZA is given 3 times a year.

Extensive real-world experience across a broad range of ages

have been treated with
SPINRAZA worldwide†

there’s someone from almost every
age group who has taken

have been treated with
SPINRAZA worldwide†

Based on commercial patients, early access patients, and clinical trial participants through September 2023.

SPINRAZA pivotal studies included patients from 3 days to 16 years of age at first dose and did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger patients.